RB1 and small cell lung carcinoma: Recently, it has been found that patients with RB1 loss of function (LOF) score low or RB1 wild in transcriptional level benefit more from immunotherapy, while non-NE subtypes cannot predict the response to immunotherapy, suggesting that RB1 functional status may be a more relevant biomarker of immune response in SCLC (44).